La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

SinoMab BioScience Bilan de santé

Santé financière contrôle des critères 1/6

SinoMab BioScience possède un total de capitaux propres de CN¥276.9M et une dette totale de CN¥423.8M, ce qui porte son ratio d'endettement à 153%. Son actif total et son passif total sont CN¥841.8M et de CN¥564.9M.

Informations clés

153.0%

Ratio d'endettement

CN¥423.78m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CN¥194.86m
Fonds propres	CN¥276.93m
Total du passif	CN¥564.87m
Total des actifs	CN¥841.80m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

Mar 04

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

Jan 28

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

Jan 01

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

Nov 30

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 3681 ( CN¥266.1M ) dépassent ses passifs à court terme ( CN¥202.7M ).

Passif à long terme: Les actifs à court terme de 3681 ( CN¥266.1M ) ne couvrent pas ses passifs à long terme ( CN¥362.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 3681 ( 82.7% ) est considéré comme élevé.

Réduire la dette: Le ratio d'endettement de 3681 est passé de 2.6% à 153% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 3681 dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 3681 dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 6.9 % chaque année

SinoMab BioScience Bilan de santé

Santé financière contrôle des critères 1/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

First half 2024 earnings released: CN¥0.085 loss per share (vs CN¥0.13 loss in 1H 2023)

SinoMab BioScience Limited to Report First Half, 2024 Results on Aug 19, 2024

SinoMab BioScience Limited Announces First Patient Dosed in A Phase 1b Clinical Trial of SM17 in China

SinoMab BioScience Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: CN¥0.24 loss per share (vs CN¥0.29 loss in FY 2022)

SinoMab BioScience Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China

SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China

Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE

Sinomab Bioscience Limited announces Change of Non-Executive Directors

New minor risk - Financial position

SinoMab BioScience Limited to Report First Half, 2023 Results on Aug 21, 2023

Sinomab Bioscience Limited Announces IND Application for SM17 Accepted by NMPA CDE

SinoMab BioScience Limited Announces Filing and Acceptance of Investigational New Drug Application for SM17 by the Center for Drug Evaluation of the National Medical Products Administration of China

SinoMab BioScience Limited Announces Executive Changes

Less than half of directors are independent

Sinomab Bioscience Limited Announces Enrollment in Phase I First-In-Human (FIH) Clinical Trial

Sinomab Bioscience Limited Announces Enrollment in Phase I First-In-Human (FIH) Clinical Trial

Sinomab Bioscience Limited Announces IND Approval for SN1011 by National Medical Products Administration of China

SinoMab BioScience Limited Announces First Healthy Subject Dosed in A Phase I Clinical Trial of SM17 in the U.S

SinoMab BioScience Limited Announces Retirement of Mr. Senlin LIU as Non-Executive Director

Less than half of directors are independent

Sinomab Bioscience Limited Announces an Investigational New Drug Application for SN1011

SinoMab BioScience Limited, Annual General Meeting, Jun 13, 2022

SinoMab BioScience Limited Provides an Update in Relation to Group's Key Products, SM17

SinoMab BioScience Limited Files Investigational New Drug Application SN1011

SinoMab BioScience Limited Announces SM03 Completion of Enrollment in Phase III Clinical Trial in China

SinoMab BioScience Limited to Report Fiscal Year 2020 Results on Mar 22, 2021

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

New 90-day high: HK$4.70

Sinomab Bioscience Limited Announces First Healthy Subject Dosed in A Phase I Clinical Trial of SN1011 in China

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

SinoMab BioScience Limited announced that it expects to receive HKD 100 million in funding from Haiyao International Group Limited

New 90-day high: HK$3.60

SinoMab BioScience Limited Announces Executive Changes

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

New 90-day low: HK$3.15

SinoMab BioScience Limited to Report First Half, 2020 Results on Aug 24, 2020

New 90-day low - HK$3.39

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines